Insurers warn individual mandate repeal will raise premiums, drive more away from ACA markets

Health insurers expect the repeal of the Affordable Care Act (ACA)’s individual mandate will make the individual insurance market worse, particularly for customers who don’t have employer-sponsored coverage but make too much money to receive subsidies to lower their premiums.

Fifteen companies responded to the Huffington Post when asked to assess the impact of repealing the mandate, which Republicans seek to do as part of their broader tax cut plan now being discussed between the House and Senate. The general consensus was premiums would have to be raised and more insurers may decide to leave the ACA exchanges altogether, leaving customers with fewer choices at higher prices.

“Let’s assume for a second that you eliminate the mandate and so those healthy people decide to sit out, whether they need a subsidy or not, the pool shrinks,” said Jim Havens, senior vice president of individual and senior markets for Premera Blue Cross. “That means that the people left are people who either intend to use it or think they will be using it, which is going to make it more expensive.”

Other companies think it won’t have much of an impact, as the availability of subsidies will keep people who qualify for them in the market.

“We know our block of business is using their healthcare,” said Lisa Carson, senior director of market strategy at Sioux Falls, South Dakota-based Sanford Health Plan.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup